C1orf49 Inhibitors
C1orf49 inhibitors encompass a diverse array of chemical compounds that interfere with various signaling pathways, ultimately leading to a decline in the functional activity of C1orf49. Staurosporine, LY 294002, and Wortmannin target kinase-related pathways, with the former being a broad-spectrum kinase inhibitor that may reduce C1orf49 activity if it's regulated by protein phosphorylation, while the latter two specifically inhibit PI3K, potentially diminishing C1orf49 activity as part of the PI3K/AKT signaling cascade. Rapamycin, by inhibiting mTOR, may impact C1orf49 activity if there is involvement within the mTOR pathway. Similarly, inhibitors targeting different components of the MAPK pathway, including PD 98059, SB 203580, SP600125, and U0126, could also indirectly lead to decreased C1orf49 function, assuming a regulatory relationship between C1orf49 and the MAPK pathway.
Further, PP 2 as an Src kinase inhibitor and Bortezomib as a proteasome inhibitor could result in the reduction of C1orf49 activity by affecting upstream signaling or protein stability that regulates C1orf49. Fluticasone propionate, aspecific Gs alpha inhibitor, could attenuate C1orf49 activity by altering the G protein-coupled receptor signaling that involves Gs alpha subunit. Lastly, Chelerythrine, which inhibits PKC, could potentially lead to decreased C1orf49 activity if PKC-mediated pathways regulate the protein. Collectively, these inhibitors exert their effects by diminishing signaling pathways or cellular processes that are presumed to regulate or affect the activity of C1orf49, thereby indirectly inhibiting the protein without affecting its expression levels. Each inhibitor, by acting on its specific target, contributes to a concerted downregulation of C1orf49 functionality through a multi-faceted approach to pathway interference.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. By inhibiting a broad range of kinases, it diminishes the phosphorylation of various proteins, potentially leading to reduced activity of C1orf49 if it is regulated by protein phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it reduces the PI3K/AKT signaling pathway activity, which could lead to diminished functional activity of C1orf49 if it is involved in this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. It acts similarly to LY294002, leading to diminished AKT activation and potentially reducing C1orf49 activity if it is downstream of AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it impacts the mTOR signaling pathway, which could reduce the activity of C1orf49 if it is associated with this pathway or affected by mTOR activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. If C1orf49 activity is modulated by the MAPK pathway, inhibiting MEK would likely lead to diminished C1orf49 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, which could decrease the functional activity of C1orf49 if it plays a role in stress response or is modulated by p38 MAPK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK family. Inhibition of JNK would likely decrease the activity of C1orf49 if it is modulated by JNK signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP 2 is an Src family kinase inhibitor. If C1orf49 activity is dependent on Src kinase signaling, PP 2 would result in decreased C1orf49 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting proteasomal degradation, it could lead to decreased levels of proteins that regulate C1orf49 activity, thereby indirectly diminishing its functional activity. | ||||||
Fluticasone propionate | 80474-14-2 | sc-218517 | 10 mg | $180.00 | ||
Fluticasone propionate is a potent and selective inhibitor of Gs alpha subunit of G proteins. If C1orf49 is regulated through G protein-coupled receptor signaling involving Gs alpha, Fluticasone propionate would lead to a decrease in C1orf49 activity. | ||||||